Debt-laden conglomerate gets banks including ICBC, China Minsheng, Shanghai Pudong and HSBC to pony up funds for high-tech, advanced manufacturing and biomedical sectors

Acquisition of contract development and manufacturing organization and shareholder loan will expand the Chinese drugmaker’s footprint in Europe

Billionaire Guo Guangchang says the sprawling conglomerate has 270 billion yuan in total assets versus 100 billion yuan in liabilities at the group level

Offloading Nangang Iron & Steel may be the beginning of the end, or a fresh start for the debt-laden giant

Chinese conglomerate with stakes in Club Med, Lanvin, drugs, retailing and tourism moves to shore up balance sheet and dumps Moody’s following downgrades

The conglomerate will transfer its 60% shareholding in Nanjing Nangang Iron & Steel United to metals giant Jiangsu Shagang Group

A record number of Chinese cities report Covid cases during the National Day holiday. JD.com’s Richard Liu settles a lawsuit with his rape accuser

Lending syndicate including ICBC and China Minsheng Bank may start releasing credit next month to bail out troubled conglomerate, banking sources say

Xi will make his first foreign trip since the Covid-19 pandemic began

The conglomerate says a notice from the local state assets administrator was a routine request for information

CanSino’s net income fell 99% in the first half, while Fosun reported a decline of more than one-third

There’s a long way to go in rolling out the advanced shots for China as Western companies control patents and Chinese companies face technological barriers

For want of an additional $249 million demanded by creditors, the indebted tour operator filed for liquidation this week

Chinese conglomerate plans to expand luxury fashion portfolio with purchase of Belgian gem appraiser

Financial asset acquisition is second made by the Chinese conglomerate in the Latin American country

Investors in bike-sharing startup still see opportunity in China’s smaller cities despite industry’s rapid expansion

The conglomerate becomes the second-largest shareholder of one of China’s oldest beer makers

Yescarta cell therapy has been approved in U.S., but Chinese launch has no set date

Chinese conglomerate Fosun is selling most of its remaining stake in Minsheng, unwinding investment made in 2011